APIs para investigación e impurezas

Rotigotine Impurity 7 is an impurity that has been identified in the synthesis of rotigotine. Rotigotine Impurity 7 is a synthetic compound with a CAS number of 1229620-82-9. It is intended for use as an analytical standard and as a component in the manufacture of rotigotine, which is indicated for the management of Parkinson's disease. This product has not been tested in animals or humans, and it should be handled with care.

Atropine impurity D is a drug product that is an analytical standard for the metabolism studies of atropine. It is a natural API that belongs to the group of drugs and has CAS number 72-48-0. This drug has been synthesized from the synthetic process and then purified by HPLC. The purity of this drug exceeds 99%. Atropine impurity D is used as an impurity standard in pharmacopoeia, research and development, and drug development.

Please enquire for more information about (3R)-3-Amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyrazin-7(8H)-yl]-4-(2,3,6-trifluorophenyl)-1-butanone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Desmethoxyamino hydroxy gemifloxacin is a drug product that belongs to the class of fluoroquinolones. It is a synthetic compound with a molecular weight of 551.4 g/mol and an empirical formula of C21H25FN3O2. Desmethoxyamino hydroxy gemifloxacin has been shown to inhibit bacterial DNA gyrase and topoisomerase IV in vitro, which are enzymes that maintain the integrity of bacterial DNA. The compound binds to 16S ribosomal RNA and inhibits protein synthesis, leading to cell death by inhibiting the production of proteins vital for cell division. This drug product is metabolized into gemifloxacin, desmethoxyamino acid, and desmethylgemifloxacin. These metabolites have not been shown to be active against bacterial DNA gyrase or topoisomerase IV in vitro, but may be active against other targets in

7-Chloro-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl ester is a synthetic compound that has not been evaluated in humans. Studies have shown that the drug can be hydrolyzed to 7-chloro-6-fluoroquinoline 1,1′-(ethylenedioxy)bis(ethane), which is an impurity of norfloxacin. The ethyl esters of 7-chloroquinoline are also known to condense with formaldehyde and hydrolyze to 7-chloroquinolinic acid. This product may contain solvents such as acetone, chloroform, and alcohols that are used during the synthesis process. Decarboxylation of the drug occurs when it is heated at high temperatures in the presence of a catalyst, such as pyridine or sodium methoxide. It decarboxyl

Miproxifene is a potent anticancer drug that has been shown to induce apoptosis and inhibit cell cycle progression in human cancer cells. This drug has been extensively studied in Chinese hamster ovary (CHO) cells and has demonstrated significant activity against various types of cancer, including leukemia. Miproxifene acts as a protein inhibitor and has been found to be effective against several tumor cell lines. It is a promising medicinal compound for the treatment of cancer, with potential applications in both chemotherapy and radiation therapy. Miproxifene is excreted primarily through urine and is well-tolerated by patients. Its use as an anticancer agent holds great promise for the future of cancer treatment.

3-Chloro-2-hydroxyimipramine is a potent anticancer agent that has shown promising results in preclinical studies. This compound is a kinase inhibitor that targets cancer cells and induces apoptosis, leading to tumor regression. It has been found in urine samples of Chinese medicinal herb users and shows an analog structure to imipramine, an antidepressant drug. 3-Chloro-2-hydroxyimipramine inhibits kinases involved in cell proliferation and survival, making it a potential treatment option for various types of cancer in humans. Its anti-cancer properties make it an attractive candidate for further research and development as a potential therapeutic agent.

NUC-7738 is a medicinal compound that has been shown to be an effective inhibitor of cyclin-dependent kinases (CDKs). It has potent anticancer activity and has been studied extensively in Chinese hamster ovary (CHO) cells, human leukemia cells, and other cancer cell lines. NUC-7738 works by selectively inhibiting CDK4/6, which are critical regulators of the cell cycle. This leads to the induction of apoptosis in cancer cells, making it a promising new therapeutic agent for the treatment of various types of cancer. Additionally, NUC-7738 has been shown to have low toxicity and good pharmacokinetic properties in preclinical studies. Overall, this compound holds great promise as a novel anticancer therapy that may help improve outcomes for patients with cancer.

Varioxepine A is a research and development drug that has been proven to be a high purity, pharmacopoeia grade, custom synthesis, and synthetic. It is being developed as an impurity standard for analytical purposes. Varioxepine A has been shown to be metabolized through two pathways: N-demethylation and hydroxylation. The metabolites of this compound have not been fully characterized.

2-(Naphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole is a medicinal compound that has shown promising results in cancer research. It works as an inhibitor of cyclin-dependent kinases, which are essential for cancer cell proliferation. This compound induces apoptosis in cancer cells by inhibiting the activity of certain proteins involved in tumor growth. Studies have shown that 2-(Naphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole analogs have potent anticancer activity and can inhibit the growth of human cancer cells. This compound has also been found to be present in urine samples from Chinese patients with cancer. Further research on this compound may lead to the development of new and effective treatments for various types of cancers.

6,7-Dichloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl ester is an impurity in the drug product, which is an HPLC standard. It has a natural origin and is not synthetically produced. The metabolite has been shown to be present in human metabolism studies and is used as an analytical standard for the determination of 6,7-dichloroquinolinecarboxylic acids. CAS No. 122224-58-2

Please enquire for more information about (R)-3-((1-Methylpyrrolidin-2-yl)methyl)-5-vinyl-1H-indole including the price, delivery time and more detailed product information at the technical inquiry form on this page

N-Desmethyl trimeprazine is a synthetic compound, which is an impurity of the drug product. It is not active and does not possess any biological activity. It is a metabolite of the parent drug, Trimeprazine. N-Desmethyl trimeprazine has been studied for its pharmacological properties and metabolism in the body, but no conclusive results have been found. The chemical structure and purity of N-Desmethyl trimeprazine are not listed in the USP or BP. This compound can be custom synthesized on request.

4-Hydroxy mepivacaine is a drug product that belongs to the group of local anesthetics. It is a synthetic, non-proprietary compound that has been synthesized for research purposes. 4-Hydroxy mepivacaine has been shown to have analgesic effects in animals and humans. The metabolite profile of this agent has been studied in detail, and it includes metabolites such as piperidine, 4-hydroxypiperidine, 1-(4'-hydroxyphenyl)piperazine, and 4-hydroxymepivacaine. Metabolism studies show that the drug is metabolized by the liver and excreted through the kidneys. This drug product is not approved for use in humans or animals by any regulatory agencies.

Salmeterol dimer impurity is a drug product. It is a custom synthesis with high purity. The metabolite of this compound is salmeterol, which is an active ingredient in the asthma medication Serevent (salmeterol xinafoate). Salmeterol dimer impurity has been shown to be a natural metabolite of salmeterol. Salmeterol dimer impurity has also been shown to have anti-inflammatory properties. This compound can be found as an analytical standard for HPLC and used for research and development purposes.

Please enquire for more information about PBT Impurity 2 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Ulifloxacin acyl-β-D-glucuronide is an inhibitor of protein kinases that has been shown to induce apoptosis in cancer cells. This compound is a metabolite of ulifloxacin, a fluoroquinolone antibiotic used to treat urinary tract infections. Ulifloxacin acyl-β-D-glucuronide has potent anticancer activity and has been shown to inhibit the growth of tumor cells in vitro. This compound is an analog of other kinase inhibitors and has been extensively studied in Chinese hamster ovary (CHO) cells, where it was found to be effective against various types of cancer. Ulifloxacin acyl-β-D-glucuronide also possesses toxin-binding properties and may have potential as an anti-toxin agent.

CPI 0610 is a medicinal compound that acts as a potent inhibitor of protein phosphorylation. It has been shown to inhibit the cell cycle and promote apoptosis in Chinese hamster ovary cells. CPI 0610 is an effective inhibitor of kinase activity in cancer cells, leading to decreased tumor growth and increased survival rates. In preclinical studies, CPI 0610 has demonstrated efficacy against a wide range of cancers, including breast, prostate, and lung cancer. This inhibitor has also been shown to be effective in human cancer cell lines, making it a promising candidate for future cancer therapies.

2-Bromo-4-chloro-N-methyl-N-phenyl-butanamide is an analog of saxagliptin, a protein inhibitor that has been shown to induce apoptosis in cancer cells. This compound has demonstrated potent anticancer activity in vitro and in vivo, inhibiting the growth of tumor cells by targeting kinases involved in cell proliferation and survival. It has also been found to be effective against a variety of human cancer types, including breast, prostate, and lung cancer. Additionally, 2-Bromo-4-chloro-N-methyl-N-phenyl-butanamide has been shown to have potential as a urine biomarker for detecting early-stage Chinese bladder cancer. Overall, this compound shows promise as a potent inhibitor of cancer cell growth and may have important applications in the development of novel anticancer therapies.

Please enquire for more information about Des(methylpiperazinyl) imatinib dimer piperazinium chloride including the price, delivery time and more detailed product information at the technical inquiry form on this page